Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023

Rhea-AI Summary

Akoya Biosciences (Nasdaq: AKYA) announced it will release its financial results for Q1 2023 on May 8, 2023, after market close. The management will hold a conference call at 5:00 p.m. ET to discuss the outcomes. Interested investors are advised to register for the call a day in advance. Akoya, known as The Spatial Biology Company®, specializes in spatial phenotyping solutions that enhance researchers' understanding of biology and human health. Their key products include PhenoCycler™, PhenoImager™ Fusion, and PhenoImager HT, which are aimed at various research needs.

News Market Reaction – AKYA

-4.30%

-4.30% Session move

In the trading session that priced this news, AKYA declined 4.30%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MARLBOROUGH, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8^th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.

Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com

Media Contact:
Christine Quern
(617) 650-8497
media@akoyabio.com

FAQ

When will Akoya Biosciences release its financial results for Q1 2023?

Akoya Biosciences will release its financial results for Q1 2023 on May 8, 2023, after market close.

What time is the conference call for Akoya's Q1 2023 financial results?

The conference call for Akoya's Q1 2023 financial results will be held at 5:00 p.m. ET.

How can investors listen to Akoya's conference call?

Investors can register online to listen to Akoya's conference call, with a recommendation to register at least a day in advance.

What products does Akoya Biosciences offer?

Akoya offers several spatial phenotyping solutions, including PhenoCycler™, PhenoImager™ Fusion, and PhenoImager HT.